Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.

Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N.

Cancer Chemother Pharmacol. 2019 Jun 11. doi: 10.1007/s00280-019-03887-2. [Epub ahead of print] Review.

PMID:
31187168
2.

Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer.

Marzo T, Massai L, Pratesi A, Stefanini M, Cirri D, Magherini F, Becatti M, Landini I, Nobili S, Mini E, Crociani O, Arcangeli A, Pillozzi S, Gamberi T, Messori L.

ACS Med Chem Lett. 2019 Feb 7;10(4):656-660. doi: 10.1021/acsmedchemlett.9b00007. eCollection 2019 Apr 11.

PMID:
30996813
3.

RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.

Mini E, Lapucci A, Perrone G, D'Aurizio R, Napoli C, Brugia M, Landini I, Tassi R, Picariello L, Simi L, Mancini I, Messerini L, Magi A, Pinzani P, Mazzei T, Tonelli F, Nobili S.

Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32326. [Epub ahead of print]

PMID:
30973654
4.

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN.

Clin Cancer Res. 2019 Apr 9. doi: 10.1158/1078-0432.CCR-18-3661. [Epub ahead of print]

PMID:
30967420
5.

Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.

Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E.

Mol Clin Oncol. 2018 Dec;9(6):635-639. doi: 10.3892/mco.2018.1729. Epub 2018 Oct 1.

6.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F.

Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047.

PMID:
30486741
7.

A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.

Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E.

BMC Cancer. 2018 Oct 22;18(1):1024. doi: 10.1186/s12885-018-4919-z.

8.

The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice.

Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, Ecca F, Dreussi E, Palazzari E, Guardascione M, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R, Cecchin E.

Clin Pharmacol Ther. 2019 Apr;105(4):994-1002. doi: 10.1002/cpt.1257. Epub 2018 Nov 22.

PMID:
30339275
9.

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.

De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, Romanato L, Cecchin E, Toffoli G.

Front Pharmacol. 2018 Oct 4;9:1101. doi: 10.3389/fphar.2018.01101. eCollection 2018.

10.

Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer.

Bartolini I, Ringressi MN, Melli F, Risaliti M, Brugia M, Mini E, Batignani G, Bechi P, Boni L, Taddei A.

Gastroenterol Res Pract. 2018 Jul 11;2018:5353727. doi: 10.1155/2018/5353727. eCollection 2018.

11.

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB.

JCO Precis Oncol. 2018 Jun 13;2018. doi: 10.1200/PO.17.00241.

12.

Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study.

Magherini F, Fiaschi T, Valocchia E, Becatti M, Pratesi A, Marzo T, Massai L, Gabbiani C, Landini I, Nobili S, Mini E, Messori L, Modesti A, Gamberi T.

Oncotarget. 2018 Jun 15;9(46):28042-28068. doi: 10.18632/oncotarget.25556. eCollection 2018 Jun 15.

13.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

PMID:
29921730
14.

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.

J Thorac Oncol. 2018 Aug;13(8):1146-1155. doi: 10.1016/j.jtho.2018.04.025. Epub 2018 May 3.

PMID:
29730379
15.

ERRATUM.

Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.

Oncol Res. 2018 Mar 5;26(2):333-334. doi: 10.3727/096504018X15187172557369.

PMID:
29514732
16.

Selection and characterization of a human ovarian cancer cell line resistant to auranofin.

Landini I, Lapucci A, Pratesi A, Massai L, Napoli C, Perrone G, Pinzani P, Messori L, Mini E, Nobili S.

Oncotarget. 2017 Oct 9;8(56):96062-96078. doi: 10.18632/oncotarget.21708. eCollection 2017 Nov 10.

17.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.

18.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.

JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.

19.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
20.

The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.

Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.

Oncol Res. 2017 Nov 2;25(9):1441-1451. doi: 10.3727/096504017X14926854178616. Epub 2017 Apr 20.

PMID:
28429680
21.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw272. Print 2017 May.

22.

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators.

Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687.

PMID:
28031175
23.

Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells.

Leto I, Coronnello M, Righeschi C, Bergonzi MC, Mini E, Bilia AR.

ChemMedChem. 2016 Aug 19;11(16):1745-51. doi: 10.1002/cmdc.201500586. Epub 2016 Mar 21.

PMID:
26999297
24.

Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy.

Di Cesare Mannelli L, Zanardelli M, Landini I, Pacini A, Ghelardini C, Mini E, Bencini A, Valtancoli B, Failli P.

Free Radic Biol Med. 2016 Apr;93:67-76. doi: 10.1016/j.freeradbiomed.2016.01.023. Epub 2016 Jan 28.

PMID:
26828020
25.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P.

JAMA Oncol. 2016 May 1;2(5):643-653. doi: 10.1001/jamaoncol.2015.5225.

PMID:
26768652
26.

Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: a first insight.

Garziera M, Catamo E, Crovella S, Montico M, Cecchin E, Lonardi S, Mini E, Nobili S, Romanato L, Toffoli G.

Int J Immunogenet. 2016 Feb;43(1):32-9. doi: 10.1111/iji.12243. Epub 2015 Dec 21.

PMID:
26752414
27.

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G.

PLoS One. 2015 Dec 3;10(12):e0144000. doi: 10.1371/journal.pone.0144000. eCollection 2015.

28.

Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives.

Serratrice M, Maiore L, Zucca A, Stoccoro S, Landini I, Mini E, Massai L, Ferraro G, Merlino A, Messori L, Cinellu MA.

Dalton Trans. 2016 Jan 14;45(2):579-90. doi: 10.1039/c5dt02714d.

PMID:
26609781
29.

The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents.

Stivarou T, Cipolleschi MG, D'Amico M, Mannini A, Mini E, Rovida E, Dello Sbarba P, Olivotto M, Marzi I.

Oncotarget. 2015 Oct 13;6(31):31985-96. doi: 10.18632/oncotarget.5155.

30.

In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment.

Cialdai F, Landini I, Capaccioli S, Nobili S, Mini E, Lulli M, Monici M.

J Photochem Photobiol B. 2015 Oct;151:285-96. doi: 10.1016/j.jphotobiol.2015.08.003. Epub 2015 Aug 11.

PMID:
26355716
31.

[Medical residency program: perceptions of medical residents in hospitals of Lima and Callao].

Miní E, Medina J, Peralta V, Rojas L, Butron J, Gutiérrez EL.

Rev Peru Med Exp Salud Publica. 2015 Apr-Jun;32(2):303-10. Spanish.

32.

Emerging drugs in refractory colorectal cancer.

Nobili S, Galletta A, Brugia M, Tassi R, Petreni P, Landini I, Mini E.

Future Med Chem. 2015 Aug;7(12):1491-501. doi: 10.4155/fmc.15.85. Epub 2015 Aug 21. Review.

PMID:
26293581
33.

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.

Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S, Cecchin E.

Int J Cancer. 2015 Dec 15;137(12):2971-80. doi: 10.1002/ijc.29654. Epub 2015 Jul 14.

34.

Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues.

Riganti C, Mini E, Nobili S.

Front Oncol. 2015 May 11;5:105. doi: 10.3389/fonc.2015.00105. eCollection 2015. No abstract available.

35.

Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication.

Gamberi T, Magherini F, Fiaschi T, Landini I, Massai L, Valocchia E, Bianchi L, Bini L, Gabbiani C, Nobili S, Mini E, Messori L, Modesti A.

Mol Biosyst. 2015 Jun;11(6):1653-67. doi: 10.1039/c5mb00008d.

PMID:
25906354
36.

In vitro assessment of antibody-conjugated gold nanorods for systemic injections.

Centi S, Tatini F, Ratto F, Gnerucci A, Mercatelli R, Romano G, Landini I, Nobili S, Ravalli A, Marrazza G, Mini E, Fusi F, Pini R.

J Nanobiotechnology. 2014 Dec 5;12:55. doi: 10.1186/s12951-014-0055-3.

37.

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.

Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G.

Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21.

PMID:
25331073
38.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J; PETACC-8 Study Investigators.

Ann Oncol. 2014 Dec;25(12):2378-85. doi: 10.1093/annonc/mdu464. Epub 2014 Oct 6. Erratum in: Ann Oncol. 2015 Apr;26(4):822-5.

PMID:
25294886
39.

Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.

Dei S, Coronnello M, Floriddia E, Bartolucci G, Bellucci C, Guandalini L, Manetti D, Romanelli MN, Salerno M, Bello I, Mini E, Teodori E.

Eur J Med Chem. 2014 Nov 24;87:398-412. doi: 10.1016/j.ejmech.2014.09.084. Epub 2014 Sep 30.

PMID:
25282263
40.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators.

Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

41.

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.

Ann Oncol. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12.

PMID:
24728035
42.

Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c).

Gamberi T, Massai L, Magherini F, Landini I, Fiaschi T, Scaletti F, Gabbiani C, Bianchi L, Bini L, Nobili S, Perrone G, Mini E, Messori L, Modesti A.

J Proteomics. 2014 May 30;103:103-20. doi: 10.1016/j.jprot.2014.03.032. Epub 2014 Apr 3.

PMID:
24705091
43.

Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents.

Messori L, Marchetti L, Massai L, Scaletti F, Guerri A, Landini I, Nobili S, Perrone G, Mini E, Leoni P, Pasquali M, Gabbiani C.

Inorg Chem. 2014 Mar 3;53(5):2396-403. doi: 10.1021/ic401731a. Epub 2014 Feb 18.

PMID:
24547701
44.

Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations.

Righeschi C, Coronnello M, Mastrantoni A, Isacchi B, Bergonzi MC, Mini E, Bilia AR.

Colloids Surf B Biointerfaces. 2014 Apr 1;116:121-7. doi: 10.1016/j.colsurfb.2013.12.019. Epub 2014 Jan 6.

PMID:
24462780
45.

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.

Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P.

J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004.

PMID:
24316553
46.

Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.

Nobili S, Napoli C, Puccini B, Landini I, Perrone G, Brugia M, Benelli G, Doria M, Martelli M, Finolezzi E, Di Rocco A, Del Fava E, Rigacci L, Di Lollo S, Bosi A, Mini E.

Leuk Lymphoma. 2014 Sep;55(9):2071-8. doi: 10.3109/10428194.2013.866665. Epub 2014 Feb 24.

PMID:
24289107
47.

New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).

Orlandi F, Coronnello M, Bellucci C, Dei S, Guandalini L, Manetti D, Martelli C, Romanelli MN, Scapecchi S, Salerno M, Menif H, Bello I, Mini E, Teodori E.

Bioorg Med Chem. 2013 Jan 15;21(2):456-65. doi: 10.1016/j.bmc.2012.11.019. Epub 2012 Nov 24.

PMID:
23245571
48.

The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.

Guidi F, Modesti A, Landini I, Nobili S, Mini E, Bini L, Puglia M, Casini A, Dyson PJ, Gabbiani C, Messori L.

J Inorg Biochem. 2013 Jan;118:94-9. doi: 10.1016/j.jinorgbio.2012.10.003. Epub 2012 Oct 14.

PMID:
23142974
49.

[Self-medication behavior among pregnant women user of the Instituto Nacional Materno Perinatal, Peru 2011].

Miní E, Varas R, Vicuña Y, Lévano M, Rojas L, Medina J, Butron J, Aranda R, Gutierrez EL.

Rev Peru Med Exp Salud Publica. 2012 Jun;29(2):212-7. Spanish.

50.

Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives.

Serratrice M, Cinellu MA, Maiore L, Pilo M, Zucca A, Gabbiani C, Guerri A, Landini I, Nobili S, Mini E, Messori L.

Inorg Chem. 2012 Mar 5;51(5):3161-71. doi: 10.1021/ic202639t. Epub 2012 Feb 17.

PMID:
22339487

Supplemental Content

Support Center